

1 **Loss of severe respiratory syncytial virus infection-associated antibody function during the**
2 **peak of the COVID-19 pandemic mitigation measures**

3
4 Bahaa Abu-Raya*^{1,2}, Frederic Reicherz*^{1,2,4}, Christina Michalski^{1,2}, Abdelilah Majdoubi^{1,2}, Liam
5 Golding^{1,2}, Marina Vienta^{1,2}, Madison Granoski³, Aleksandra Stojic³, David J Marchant³, Pascal
6 M. Lavoie^{1,2}

7
8 ¹ British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada

9 ² Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver,
10 British Columbia, Canada

11 ³ Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology,
12 Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.

13 ⁴ Department of Pediatrics, Children's Hospital Datteln, University of Witten/Herdecke,
14 Germany

15
16 *First co-authors

17
18 **Corresponding author:**

19 Bahaa Abu-Raya, MD, PhD
20 Department of Pediatrics, University of British Columbia
21 British Columbia Children's Hospital Research Institute

22

23 **ABSTRACT**

24 Studies have linked reduced respiratory syncytial virus-specific Fc-mediated phagocytic function
25 and complement deposition to more severe infection. This study shows a loss of these functions
26 during the first year of COVID-19 pandemic. These findings corroborate other data supporting a
27 general waning of RSV antibody functions in absence of viral circulation.

28 Respiratory syncytial virus (RSV) is a major public health concern and a leading cause of
29 morbidity and mortality from lower respiratory tract infection (LRTI) among young children and
30 frail elderly older than 65 years of age [1]. Antibodies protect against RSV disease through
31 antigen-specific, Fab-mediated antibody interactions responsible for virus capture and
32 neutralization [2]. Based on studies in non-human primates challenged with RSV and a human
33 vaccine trial, Fc-mediated antibody functions mediate effector responses against RSV, including
34 phagocytosis of viral particle and complement-deposition, and are important for protection
35 against severe RSV LRTI [3] [4]. Levels of pre-fusion RSV fusion (F) IgG levels and
36 neutralizing titers against RSV A have been shown to decline significantly during the peak of the
37 COVID-19 pandemic measures, during the nearly complete absence of RSV circulation [5] [6],
38 suggesting that the duration of the protective antibody immunity to RSV is relatively short-lived.
39 Authors of a modeling study that was informed by epidemiological observations have estimated
40 that RSV immunity against symptomatic re-infection lasts between 6 to 12 months [7]. These
41 observations have clinical implications, indicating that ongoing viral exposure may be required
42 to maintain high antibody levels within populations. Furthermore, while decreased RSV antibody
43 neutralization may explain the increase in symptomatic pediatric RSV cases, it does not explain
44 well the corresponding increase in hospitalizations observed in young children following the
45 relaxing of pandemic measures [8, 9]. This study specifically sought to compare key RSV-
46 specific Fc-mediated functions (i.e., antibody-dependent cellular phagocytosis [ADCP],
47 antibody-dependent complement deposition [ADCD], and antibody-dependent neutrophil
48 phagocytosis [ADNP]) before and after a period of lack of RSV circulation in BC.

49

50

51 **MATERIALS AND METHODS**

52 **Sample description, laboratory analysis and ethics:** Analyses were carried out on paired
53 serum samples collected from women 18 to 51 years old during the complete pandemic-related
54 lockdown in BC, Canada, between May to June 2020, and nearly one year later, from February
55 to May 2021, as described (8). ADCP, ADCD and ADNP assays were performed as described
56 (Supplementary Methods, Supplementary Figure 1, Supplementary Figure 2, Supplementary
57 Figure 3). The study was approved by University of British Columbia Children's and Women's
58 Hospital Research Ethics Board (H20-01205, H18-01724). All participants provided informed
59 consent for these studies.

60 **Statistical analysis:** Log-transformed data for ADCP, ADCD and ADNP were compared
61 between the 2020 and the 2021 outcomes, by paired t-test. Correlations between fold-changes in
62 ADCP, ADCD and ADNP, and previously published [5] pre-fusion RSV F protein IgG levels
63 and RSV A live virus microneutralization outcomes (expressed antibody titer needed to achieve
64 95% viral neutralization, or NT95) from the same individuals in 2021 vs 2020 were estimated
65 using Pearson correlation, where statistical significance levels were adjusted for multiple
66 comparisons using the Bonferroni method ($p < 0.005$). To explore functional relationships
67 between RSV antibody outcomes, unsupervised hierarchical clustering was performed. Results
68 for 2020 and 2021 were independently displayed to enable visualization of the relationship
69 between the years and clusters of functions and levels of RSV antibodies. R version 4.1.2 was
70 used for all analyses.

71

72

73

74 **RESULTS**

75 The median age of the women (n=18) was 37 years (interquartile range [IQR]: 28 – 41 years),
76 with a median of 277 days (IQR: 256–301) between samples collected in 2020 vs. 2021.
77 Both ADCP [geometric means: 228.7 (95% CI: 83.8 – 624.0) vs. 685.5 (95% CI: 338.6-1,388.0);
78 p=0.020] and ADCD [geometric means: 1.26 (95% CI: 0.3 – 5.1) vs. 62.8 (95% CI: 45.3 – 87.2);
79 p<0.001] scores significantly decreased in 2021 compared with 2020 (Figure 1A, 1B). However,
80 no statistically significant difference in ADNP scores were detected between the 2021 and the
81 2020 samples [geometric means: 2,741 (95% CI: 2,430 – 4-3,091) vs. 2,778 (95% CI: 2,458 –
82 3,141); p=0.870] (Figure 1C).

83
84 The correlation between fold-changes and levels of functions of RSV antibodies measured in this
85 study (ADCP, ADCD, ADNP) and those we recently published (pre-fusion RSV F protein IgG
86 levels, NT95 RSV A) [5] between 2021 vs 2020 was low to moderate and not statistically
87 indicating that these functions decreased independently of each other and of pre-fusion RSV F
88 protein IgG levels (Supplementary Figure 4, Supplementary Figure 5). The samples collected in
89 2020 and 2021 showed a separate unique cluster that displayed lower ADCP and a unique subset
90 of subjects with lower ADCD using unsupervised hierarchical clustering (Supplementary Figure
91 6).

92
93 **DISCUSSION**

94 This study adds to recent evidence, supporting a broad decline in RSV antibody functions
95 beyond antibody-mediated viral neutralization. The waning of Fc-mediated antibody functions
96 essential for cellular responses and associated with RSV LRTI may herald more severe RSV
97 outcomes, and not just an increase in symptomatic RSV cases, as suggested in epidemiological

98 studies [8, 9]. Indeed, reduced RSV antibody outcomes in women of childbearing age could
99 impair the degree of RSV antibody immunity transferred to infants born during this period. The
100 waning of Fc-mediated antibody functions may also result in increased vulnerability in older
101 children who were unexposed to RSV repeatedly in a similar period. Moreover, the deficit in
102 RSV antibody outcomes observed across multiple immunological functional domains strengthen
103 the evidence for an increase pool of immunologically susceptible individuals during the strict
104 period of application of pandemic measures, especially in immunologically naïve infant who
105 lack immunological protection from acquired RSV T cell memory at this young age.

106

107 Examining RSV antibody functions in paired serum samples allowed to minimize the individual
108 variability expected for these outcomes in humans [10]. ADNP and ADCD correlated with a
109 reduction in viral load in bronchoalveolar lavage and thus protection from LRTI disease in non-
110 human primates challenged with RSV [3]. ADCP, ADNP and ADCD correlated with protection
111 from symptomatic RSV infections in humans vaccinated with the adenovirus-based
112 Ad26.RSV.preF vector [4]. Based on these studies, phagocytosis of RSV immune complexes
113 effectively activates target cells, appear necessary for a broad range of effector immune
114 responses [11], indicating that RSV protection cannot simply be assessed solely by measuring
115 RSV antibody levels [10]. Consistent with this, while we showed that antibody-mediated
116 phagocytosis declined using monocytes as the target cells (in the ADCP assay), this was not
117 shown using neutrophils as the target cells (in the ADNP assay). This finding could be due to
118 differential expression of receptors implicated in the function on target cells and their affinity to
119 RSV F IgG, and the collaboration between Fab-mediated and Fc-mediated functions [12, 13].
120 Immune system cells (e.g., monocytes, neutrophils) express Fc receptors with both activation and

121 inhibition functions and the balance of these opposed signal pathways is important in regulating
122 each effector response. THP-1 monocytes express Fc γ RII (low affinity [Fc γ RIIA activating and
123 Fc γ RIIB inhibitory]) at higher levels than Fc γ RI (high affinity, activating) and Fc γ RIII (low
124 affinity, activating) [14]. Fc γ RIIA is the isoform implicated in phagocytosis of antigen-antibody
125 complexes. Each neutrophil expresses 30,000 to 60,000 copies of Fc γ RIIA (low affinity), a level
126 that is less abundant than Fc γ RIIIB [12, 13]. It is thus possible that high expression of Fc γ RII
127 makes THP-1 cells more sensitive in capturing changes in phagocytosis activity of IgG. These
128 findings highlight the importance of examining multiple immune outcomes to obtain a more
129 complete picture of RSV antibody functions in humans.

130

131 Our study is limited by its small sample size and performed in a single region and the lack of
132 parallel clinical outcome measures. Notably, BC, experienced significant increase in RSV cases
133 with increased hospitalizations in older children after the relaxing of pandemic measures,
134 providing direct population correlates supporting the clinical relevance of the current findings
135 (9). Overall, our study sheds light on the longevity of, and provides further evidence for a
136 waning of RSV antibody outcomes associated with more severe RSV infection. Further studies
137 are needed to replicate these findings in other health jurisdictions.

138 **Figure 1: Function of RSV-specific antibodies in paired samples of women aged 18-51 years**
139 **collected in 2020 (early pandemic) and 2021 (nearly one year after the pandemic) (A-C). A)**
140 **Monocyte antibody-mediated cellular phagocytosis (ADCP); B) Antibody-mediated complement**
141 **deposition (ADCD); C) Antibody-mediated neutrophil phagocytosis (ADNP). Abbreviations:**
142 **Pre-F IgG: Prefusion RSV F protein IgG levels; NT95 A: neutralization titer 95 of RSV strain A;**
143 **ADCP: antibody-mediated cellular phagocytosis; ADCD: Antibody-mediated complement**
144 **deposition; ADNP: Antibody-mediated neutrophil phagocytosis.**

145

146

147

148

149 **Acknowledgments:** The authors wish to acknowledge BC Children’s Hospital Research Institute
150 Core Technologies and Services, Vancouver, Canada for providing the support to perform the
151 flow cytometry experiments. The authors would like to thank Dr. Jeffrey Bone, Biostatistical
152 Lead at BC Children’s Hospital Research Institute for providing input on statistical analysis.

153 **Funding:** The study was funded by the Government of Canada via its COVID-19 Immunity
154 Task Force (to PML). BA was funded by Michael Smith Health Research BC. FR was funded by
155 the German Research Foundation (Deutsche Forschungsgemeinschaft) - RE 4598/1-2. PML
156 received grant salary support from the BCCH Foundation.

157 **Author contributions:**

158 Conceptualization: BA, FR, PML

159 Methodology: Neutralization of RSV A (FR); ADCP, ADNP and ADCD (BA with input
160 from CM, PML)

161 Data analysis and visualization: BA, FR

162 Data interpretation: BA, CM, FR, MV, PML, AM, LG, MG, AS, DM

163 Writing – original draft: BA

164 Writing – review & editing and approval of submitted paper: BA, CM, FR, MV, PML,
165 AM, LG, MG, AS, DM

166

167 **Conflict of Interest:** No relevant conflicts of interest to declare.

168

169 **References:**

- 170 1. Collaborators GLRI. Estimates of the global, regional, and national morbidity, mortality,
171 and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic
172 analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* **2018**; 18(11):
173 1191-210.
- 174 2. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions
175 in infectious diseases. *Nat Rev Immunol* **2018**; 18(1): 46-61.
- 176 3. Zohar T, Hsiao JC, Mehta N, et al. Upper and lower respiratory tract correlates of
177 protection against respiratory syncytial virus following vaccination of nonhuman
178 primates. *Cell Host Microbe* **2022**; 30(1): 41-52.e5.
- 179 4. Bartsch YC, Cizmeci D, Kang J, et al. Antibody effector functions are associated with
180 protection from respiratory syncytial virus. *Cell* **2022**; 185(26): 4873-86.e10.
- 181 5. Reicherz F, Xu RY, Abu-Raya B, et al. Waning immunity against respiratory syncytial
182 virus during the COVID-19 pandemic. *J Infect Dis* **2022**.
- 183 6. den Hartog G, van Kasteren PB, Schepp RM, Teirlinck AC, van der Klis FRM, van
184 Binnendijk RS. Decline of RSV-specific antibodies during the COVID-19 pandemic.
185 *Lancet Infect Dis* **2023**; 23(1): 23-5.
- 186 7. Hawkes MT, Lee BE, Kanji JN, et al. Seasonality of Respiratory Viruses at Northern
187 Latitudes. *JAMA Netw Open* **2021**; 4(9): e2124650.
- 188 8. Nygaard U, Hartling UB, Nielsen J, et al. Hospital admissions and need for mechanical
189 ventilation in children with respiratory syncytial virus before and during the COVID-19
190 pandemic: a Danish nationwide cohort study. *Lancet Child Adolesc Health* **2023**.
- 191 9. Viñeta Paramo et al. Respiratory syncytial virus epidemiology and clinical severity
192 before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective
193 observational study. *The Lancet Regional Health - Americas*. In Press. .
- 194 10. Abu-Raya B, Reicherz F, Lavoie PM. Correlates of Protection Against Respiratory
195 Syncytial Virus Infection in Infancy. *Clin Rev Allergy Immunol* **2022**; 63(3): 371-80.
- 196 11. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-Mediated Antibody Effector
197 Functions During Respiratory Syncytial Virus Infection and Disease. *Front Immunol*
198 **2019**; 10: 548.
- 199 12. Fanger MW, Shen L, Graziano RF, Guyre PM. Cytotoxicity mediated by human Fc
200 receptors for IgG. *Immunol Today* **1989**; 10(3): 92-9.
- 201 13. Wang Y, Jönsson F. Expression, Role, and Regulation of Neutrophil Fc γ Receptors.
202 *Front Immunol* **2019**; 10: 1958.
- 203 14. Ackerman ME, Moldt B, Wyatt RT, et al. A robust, high-throughput assay to determine
204 the phagocytic activity of clinical antibody samples. *J Immunol Methods* **2011**; 366(1-2):
205 8-19.
- 206

